Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ORIC-944 |
Synonyms | |
Therapy Description |
ORIC-944 inhibits PRC2 through binding to its EED subunit, potentially leading to decreased cell proliferation and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1131). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ORIC-944 | ORIC 944|ORIC944 | ORIC-944 inhibits PRC2 through binding to its EED subunit, potentially leading to decreased cell proliferation and inhibition of tumor growth (Cancer Res 2021;81(13_Suppl):Abstract nr 1131). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05413421 | Phase I | ORIC-944 | Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Recruiting | USA | GBR | ESP | AUS | 0 |